|
Match
|
Document |
Document Title |
|
|
US20110293657 |
ENCAPSULATED VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS
The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly... |
|
|
US20120164179 |
Leishmania Challenge Model
The present invention provides a method for effectively and reproducibly infecting canines with Leishmania infantum using sand flies to vector the parasite. The inventive method comprises several... |
|
|
US20110008392 |
VACCINE TARGETS AND DELIVERY SYSTEMS FOR CRYPTOSPORIDIUM
Compositions comprising the Cryptosporidium sporozoite antigens such as SRK (‘similar to riken’), CP15 and profilin are used in vaccines against the protozoan parasite Cryptosporidim. |
|
|
US20120288552 |
COMPOSITIONS AND METHODS FOR ENCAPSULATING VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS
The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly... |
|
|
US20140161837 |
VACCINE ADJUVANT, VACCINE COMPOSITION AND METHOD FOR PREPARING A VACCINE ADJUVANT
The disclosure provides a vaccine adjuvant, including a polysaccharide derived from Antrodia camphorata (also named Antrodia cinnamomea or Taiwanofungus camphoratus) fruiting body, wherein the... |
|
|
US20110223195 |
COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS
The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use... |
|
|
US20120263746 |
USE OF AN L3 AND/OR L5 SOURCE AS A VACCINE OR AS A DIAGNOSTIC FOR A PARASITIC DISEASE
The invention relates to composition comprising an L3 and/or an L5 source and optionally an adjuvant for the preparation of a medicine for the treatment or prevention of a parasitic disease and to... |
|
|
US20110008391 |
VACCINE COMPOSITION AND IMMUNIZATION METHOD
The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, as an adjuvant, allowing the distinction between... |
|
|
US20140193459 |
VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant... |
|
|
US20130058997 |
VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant... |
|
|
US20140255448 |
VACCINE COMPOSITION AND IMMUNIZATION METHOD
The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus... |
|
|
US20110038887 |
Novel Vaccine Against Trypanosoma Cruzi Infection
The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to... |
|
|
US20110081383 |
LIVE ATTENUATED LEISHMANIA VACCINES
Targeted disruption of the centrin gene leads to attenuation of growth in the Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation... |
|
|
US20140127266 |
PLANT PRODUCED VACCINE FOR AMEBIASIS
Disclosed herein are methods of making a vaccine against Entamoeba histolytica and methods of immunizing a subject using such vaccine. Specifically exemplified are plants expressing a LecA... |
|
|
US20130017220 |
GEL VACCINE DELIVERY SYSTEM FOR TREATING POULTRY
Safe and effective gel-bead vaccines for treating domesticated birds for diseases caused by cyst-forming protozoa, especially for coccidiosis. |
|
|
US20120093871 |
MODIFIED PROTOZOAN EXPRESSING AT LEAST TWO VARIABLE SURFACE PROTEINS (VSP), A VACCINE COMPRISING IT AND PROCEDURES, USES, AND METHODS THEREOF
Modified protozoa parasites comprising simultaneous expression on its surface of at least two ariable surface proteins (VSP). The modified protozoa may also simultaneously express the complete... |
|
|
US20150182564 |
PROBIOTIC FOR AMELIORATION OF COCCIDIOSIS VACCINE REACTION
Methods for improving the health of agricultural poultry are provided. For example, methods including selecting specific bacteria to form a probiotic for the administration with coccidiosis... |
|
|
US20150165008 |
USE OF ATTENUATED STRAINS OF PARASITES FOR THE PREVENTION OR TREATMENT OF PATHOLOGIES ASSOCIATED WITH AN APICOMPLEXAN
Strains of Sarcocystidae selected from Toxoplasma spp or Neospora spp isolated from their natural environment and having an immunostimulant effect, for the use thereof in the prevention or the... |
|
|
US20110129494 |
Vaccine Formulations Comprising Saponin-containing Adjuvants
The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified... |
|
|
US20140178437 |
USE OF A FOOD ADDITIVE BASED ON AT LEAST ONE PHYTONUTRIENT FOR STIMULATING VACCINE IMMUNITY AGAINST APICOMPLEXA IN ANIMALS
The invention relates to the use of a food additive comprising at least one phytonutrient in order to stimulate vaccine immunity against apicomplexa in non-human monogastric animals, such as... |
|
|
US20100297186 |
MULTICOMPONENT OR MONOCOMPONENT VACCINE TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE OBTENTION OF IMMUNOGEN OF SAID VACCINES, AND NUCLEIC ACID USED IN SAID PROCEDURE
A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma Cruzi parasite, which is a multicomponent vaccine... |
|
|
US20120288524 |
LEISHMANIA-BASED CARRIER FOR VACCINE DELIVERY
The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a Leishmania transfected for expressing a cDNA sequence for encoding the... |
|
|
US20110111015 |
COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA
Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD 154 polypeptide capable of binding to CD4Q.... |
|
|
US20110020405 |
VACCINE COMPRISING A RIBOSOMAL PROTEIN EXTRACT (RPE) AND OPTIONALLY A TH1-PROMOTING ADJUVANT
The invention relates to composition comprising a RPE and optionally a Th1-promoting adjuvant for the preparation of a medicament for the treatment or prevention of a parasitic disease and to its use. |
|
|
US20100297173 |
PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST PROTOZOAN INFECTION AND DISEASE
Polypeptide and polynucleotide vaccines effective to treat or prevent infection of a mammal, such as a dog, a cat, or a human, by a protozoan. Methods of treatment and prevention are also... |
|
|
US20130071430 |
MICRORNA-CONTROLLED RECOMBINANT VACCINIA VIRUS AND USE THEREOF
It is intended to provide a vaccinia virus that specifically proliferates in a cancer cell and destroys the cancer cell and to provide use of the virus in cancer treatment. The present invention... |
|
|
US20110177116 |
Methods of Immunizing Pregnant Heifers at Three Months of Gestation
The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate... |
|
|
US20110262457 |
MODULATION OF THE IMMUNE RESPONSE
Methods for increasing the generation of IL-17-producing T cells (TH17) in vivo and in vitro, and enriched populations of TH17 cells for the treatment of diseases benefiting from an induced or... |
|
|
US20120258135 |
IMMUNOGENIC ANTI-INFLAMMATORY COMPOSITIONS
The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one... |
|
|
US20110091526 |
Parasite Vaccine
Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream... |
|
|
US20110177120 |
MYCOBACTERIUM TUBERCULOSIS VACCINE
The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical... |
|
|
US20130071483 |
VACCINE PRODUCED USING OPTIMIZED IMMOBILIZATION ANTIGEN cDNA OF CRYPTOCARYON IRRITANS AND PRODUCING METHOD AND USE THEREOF
The present invention provides an optimized immobilization antigen cDNA sequence of cryptocaryon irritans, which has been processed codon replacement and caused the cDNA to express in prokaryotic... |
|
|
US20120308598 |
MALARIA VACCINES BASED ON APICOMPLEXAN FERLINS, FERLIN-LIKE PROTEINS AND OTHER C2-DOMAIN CONTAINING PROTEINS
The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for... |
|
|
US20120237544 |
BACTERIAL SPORE HAVING THERAPEUTIC AGENT ADSORBED ON ITS SURFACE
The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present... |
|
|
US20150190487 |
MUTANT STRAINS OF NEOSPORA AND USES THEREOF
A mutant strain of Neospora spp, in which the function of the NcMIC3 protein and/or the function of the NcMIC1 protein is suppressed, and uses thereof in a pharmaceutical composition or in a... |
|
|
US20120141535 |
PROCESS AND COMPOSITION FOR TREATMENT OF CANINE AND HUMAN LEISHMANIASIS
Process and immune chemotherapeutic/pharmaceutical composition for treatment of canine and human Leishmaniasis comprising a vaccine containing the FML antigen (Fucose Mannose-Ligand) and saponin... |
|
|
US20140030293 |
NEW ADJUVANT
The invention relates to a new adjuvant and to its use in combination with an antigen. |
|
|
US20150165020 |
MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS
Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been... |
|
|
US20140056940 |
NOVEL ADJUVANT COMPOSITIONS
This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant... |
|
|
US20100266629 |
Cattle Reproductive Disease Vaccines
The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1... |
|
|
US20060073170 |
Vaccine complex for preventing or treating leishmaniases
A therapeutic vaccine complex for preventing or treating leishmaniases and infections mediated by intracellular pathogenic micro-organism in mammals and in particular in humans, members of the... |
|
|
US20110182847 |
USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a... |
|
|
US20110236419 |
RECOMBINANT CDV COMPOSITIONS AND USES THEREOF
The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said... |
|
|
US20120269823 |
VIRULENT ISOLATE OF NEOSPORA CANINUM AND ITS USES
The present invention relates to a new isolate of Neospora caninum and to the extracts which may be produced therefrom. Said isolate presents a high degree of attenuation, which makes it suitable... |
|
|
US20070212329 |
Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System
This invention relates to a combination therapy that finds utility in the treatment or prophylaxis of infectious diseases, cancers, autoimmune diseases and related conditions. In particular, the... |
|
|
US20090041798 |
LEISHMANIA STEROL 24-C-METHYLTRANSFERASE COMPOSITIONS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF LEISHMANIASIS
Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise Leishmania sterol 24-c-methyltransferase (SMT) polypeptides,... |
|
|
US20130216578 |
RECOMBINANT TRYPANOSOMA THEILERI PARASITE
The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant Trypanosoma theileri parasite, preferably comprising a... |
|
|
US20120128722 |
Novel Monensin Derivatives for the Treatment and Prevention of Protozoal Infections
This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of... |
|
|
US20090081157 |
Immunostimulatory Combinations for Vaccine Adjuvants
This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TN-FRSF) agonists, Toll-Like Receptor (TLR) agonists, “domain present in NAIP, CIITA, HET-E,... |
|
|
US20100310606 |
VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS
This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite... |